US adverse drug reaction surveillance 1989-1994

Pharmacoepidemiology and Drug Safety

Volumn 5, Issue 6, 1996, Pages 393-398

  Faich, Gerald A ^a  

^a Outcomes Research Corporation   (United States)

Author keywords

MedWatch; post marketing surveillance; spontaneous adverse drug reaction reporting; USA

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELBAMATE; TEMAFLOXACIN; TERFENADINE;

ADVERSE DRUG REACTION; ARTICLE; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; UNITED STATES;

EID: 0030497560     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H     Document Type: Article

References (23)

1. Faich, G. A., Lawson, D. H., Tilson, H. H. and Walker, A. Clinical trials are not enough. Journal of Clinical Research and Drug Development 1987; 1: 75-78.
2. Lenz, W. Malformations caused by drugs in pregnancy. American Journal of Diseases of Childhood 1966; 112: 99-106.
3. Ersler, A. J. and Wintrobe, M. M. Detection and prevention of drug induced blood dyscrasias. Journal of the American Medical Association 1962; 181: 114-119.
4. Maeder, T. Adverse Reactions. Wm Morrow and Co, NY, 1994.
5. Department of Health and Human Services. New drug and antibiotic regulations. Section 314.80 - Federal Regulations 1985; 50: 7452-7519.
6. Scott, H. D., Thacher-Renshaw, A., Rosenbaum, S. and Faich, G. A. Physician reporting of ADRs - Rhode Island. Journal of the American Medical Association 1990; 263: 1785-1788.
7. Rogers, A. S., Israel, E., Smith, C., Levine, D., McBean, A. M., Walente, C. and Faich, G. A. Physician knowledge, attitudes and behavior related to reporting adverse drug events. Archives of Internal Medicine 1988; 148: 1596-1600.
8. Kessler, D. Introducing MedWatch. Journal of the American Medical Association 1993; 269: 2765-2768.
9. Britt, A. L. Safety information processing at FDA. Drug Information Journal 1996; 30: 47-58.
10. Food and Drug Administration. Annual Adverse Reaction Report: 1989. Report number PB90-202607. National Technical Information Service. Springfield, Va 22161.
11. Food and Drug Administration. Annual Adverse Reaction Report: 1990. Report number PB91-173005. National Technical Information Service. Springfield, Va 22161.
12. Food and Drug Administration. Annual Adverse Reaction Report: 1991. Report number PB92-197151. National Technical Information Service. Springfield, Va 22161.
13. Food and Drug Administration. Annual Adverse Reaction Report: 1992. Report number PB93-218329. National Technical Information Service. Springfield, Va 22161.
14. Food and Drug Administration. Annual Adverse Reaction Report: 1993. Report number PB94-181153 LEU. National Technical Information Service. Springfield, Va 22161.
15. Rossi, A. C., Bosco, L., Faich, G. A., Tanner, A. and Temple, R. The importance of adverse reaction reporting by physicians: suprofen and the Flank Pain Syndrome. Journal of the American Medical Association 1988; 259: 1203-1204.
16. US General Accounting Office. FDA Drug Review: Post Approval Risks 1976-1985. General Accounting Office, Washington, DC, 1990.
17. Terfenadine FDA. Hismanal and Cardiac Arrhythmias. FDA Medical Bulletin 1993; 23(1): 2-3.
18. Gelb, L. N. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Medical Bulletin 1992; 22(1): 2.
19. Rheinstein, D. H. Reporting of adverse events. American Family Physician 1992; 46: 873-875.
20. Felbamate FDA. Recommendations for immediate withdrawal of patients from felbamate. FDA Medical Bulletin 1994; 24(2): 5.
21. Weber, J. C. P. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Advances in Inflammation Research, Vol. 6. Plainsford, K. D. and Veto, E. P. (Eds), Raven Press, New York, 1984, pp. 1-7.
22. Rossi, A. C., Hsu, J. P. and Faich, G. A. Ulcerogenicity of piroxicam. British Medical Journal 1987; 294: 147-150.
23. Baum, C., Faich, G. A., Anello, C. and Forbes, M. B. Differences in manufacturer reporting of adverse drug reactions to the FDA in 1984. Drug Information Journal 1987; 21: 257-266.